Literature DB >> 24903546

Wireless accelerometry is feasible in acute monitoring of upper limb motor recovery after ischemic stroke.

Campbell Le Heron1, Kun Fang, Jayavardhana Gubbi, Leonid Churilov, Marimuthu Palaniswami, Stephen Davis, Bernard Yan.   

Abstract

BACKGROUND: Clinical deterioration in the acute stage of ischemic stroke powerfully predicts outcome and may serve as a marker for urgent intervention. However, accurate monitoring of acute stroke patients is hampered by the lack of validated continuous monitoring devices. We sought to assess the use of wireless accelerometry in this setting, hypothesizing that stroke patients would have a greater difference in movement between upper limbs than controls and that the magnitude of correlation between upper limb movements would be negatively associated with the National Institutes of Health Stroke Scale (NIHSS) score.
METHODS: In this pilot study, 20 patients with acute ischemic stroke and unilateral upper limb weakness and 10 controls were recruited from a comprehensive stroke centre. All subjects were fitted with two 3-axis accelerometers and underwent 24 h of continuous accelerometry recording of upper limb movements and repeat NIHSS assessments. The intra-class correlation coefficient (ICC), assessing the similarity (or otherwise) of spontaneous movements in each arm was calculated. The association between NIHSS (total and motor subset scores) and the magnitude of ICC was estimated by Spearman's rank correlation, receiver-operating characteristic curve analysis was performed and the optimal diagnostic threshold value of ICC was calculated.
RESULTS: The magnitude of the ICC was significantly associated with the baseline NIHSS score (p = 0.02) and non-significantly associated with the baseline NIHSS motor score (p = 0.08). At the optimal diagnostic threshold of ICC magnitude = 0.7, wireless accelerometry distinguished patients from controls with a sensitivity of 0.95, a specificity of 0.6 and a diagnostic odds ratio of 28.5.
CONCLUSIONS: The wireless accelerometry system successfully detects a motor deficit in the setting of acute ischemic stroke, accurately differentiating patients from controls, and correlates well with the baseline NIHSS score. Its use is feasible in the acute stroke setting. Overall, it shows promise as a diagnostic tool to continuously monitor acute stroke patients but requires validation in a larger trial.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 24903546     DOI: 10.1159/000360808

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  5 in total

1.  Digital Phenotyping in Clinical Neurology.

Authors:  Anoopum S Gupta
Journal:  Semin Neurol       Date:  2022-01-11       Impact factor: 3.212

Review 2.  Wearable sensors for clinical applications in epilepsy, Parkinson's disease, and stroke: a mixed-methods systematic review.

Authors:  Dongni Johansson; Kristina Malmgren; Margit Alt Murphy
Journal:  J Neurol       Date:  2018-02-09       Impact factor: 4.849

3.  Actigraphic measurement of the upper limbs movements in acute stroke patients.

Authors:  Chiara Iacovelli; Pietro Caliandro; Marco Rabuffetti; Luca Padua; Chiara Simbolotti; Giuseppe Reale; Maurizio Ferrarin; Paolo Maria Rossini
Journal:  J Neuroeng Rehabil       Date:  2019-12-04       Impact factor: 4.262

4.  Actigraphic Measurement of the Upper Limbs for the Prediction of Ischemic Stroke Prognosis: An Observational Study.

Authors:  Giuseppe Reale; Silvia Giovannini; Chiara Iacovelli; Stefano Filippo Castiglia; Pietro Picerno; Aurelia Zauli; Marco Rabuffetti; Maurizio Ferrarin; Giulio Maccauro; Pietro Caliandro
Journal:  Sensors (Basel)       Date:  2021-04-02       Impact factor: 3.576

Review 5.  Quantification of Movement in Stroke Patients under Free Living Conditions Using Wearable Sensors: A Systematic Review.

Authors:  Mariano Bernaldo de Quirós; E H Douma; Inge van den Akker-Scheek; Claudine J C Lamoth; Natasha M Maurits
Journal:  Sensors (Basel)       Date:  2022-01-28       Impact factor: 3.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.